In parallel with these results, a recent study showed that a Merkel cell carcinoma patient who completely responded to pembrolizumab had high levels of PD-1 in both tumor infiltrating and circulating Vδ1 cells (Lien et al, 2024). This evidence concerns the gene PDCD1 and neoplasm.